BIOCRYST PHARMACEUTICALS ($BCRX) posted quarterly earnings results for Q2 2026 on Wednesday, August 5th. The company reported earnings of $0.30 per share, beating estimates of $0.12 by $0.18. The company also reported revenue of $218,250,000, beating estimates of $186,163,974 by $32,086,026.
You can see Quiver Quantitative's $BCRX stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
BIOCRYST PHARMACEUTICALS Insider Trading Activity
BIOCRYST PHARMACEUTICALS insiders have traded $BCRX stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $BCRX stock by insiders over the last 6 months:
- ALANE P BARNES (Chief Legal Officer) has made 0 purchases and 2 sales selling 212,500 shares for an estimated $1,968,750.
- THERESA HEGGIE sold 49,933 shares for an estimated $504,822
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
BIOCRYST PHARMACEUTICALS Hedge Fund Activity
We have seen 170 institutional investors add shares of BIOCRYST PHARMACEUTICALS stock to their portfolio, and 107 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TCG CROSSOVER MANAGEMENT, LLC added 11,020,968 shares (+inf%) to their portfolio in Q1 2026, for an estimated $104,919,615
- VESTAL POINT CAPITAL, LP added 4,775,000 shares (+212.2%) to their portfolio in Q1 2026, for an estimated $45,458,000
- FRAZIER LIFE SCIENCES MANAGEMENT, L.P. added 4,009,240 shares (+inf%) to their portfolio in Q1 2026, for an estimated $38,167,964
- KYNAM CAPITAL MANAGEMENT, LP removed 3,685,731 shares (-39.4%) from their portfolio in Q1 2026, for an estimated $35,088,159
- BANK OF AMERICA CORP /DE/ added 3,556,208 shares (+231.6%) to their portfolio in Q1 2026, for an estimated $33,855,100
- RFG ADVISORY, LLC removed 2,870,700 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $28,707,000
- BAKER BROS. ADVISORS LP removed 2,822,727 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $26,872,361
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
BIOCRYST PHARMACEUTICALS Government Contracts
We have seen $571,165 of award payments to $BCRX over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- PHARM - ORLADEYO: $360,000
- BEROTRALSTAT HCL 150MG CAP,ORAL (ORLADEYO).: $29,407
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.
BIOCRYST PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $BCRX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Cantor Fitzgerald issued a "Overweight" rating on 06/30/2026
To track analyst ratings and price targets for BIOCRYST PHARMACEUTICALS, check out Quiver Quantitative's $BCRX forecast page.
BIOCRYST PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $BCRX recently. We have seen 6 analysts offer price targets for $BCRX in the last 6 months, with a median target of $24.5.
Here are some recent targets:
- Brian Abrahams from RBC Capital set a target price of $14.0 on 07/07/2026
- Steven Seedhouse from Cantor Fitzgerald set a target price of $29.0 on 06/30/2026
- Andrew S. Fein from HC Wainwright & Co. set a target price of $32.0 on 06/30/2026
- Laura Chico from Wedbush set a target price of $21.0 on 05/07/2026
- Jonathan Wolleben from Citizens set a target price of $28.0 on 05/07/2026
- Serge Belanger from Needham set a target price of $16.0 on 05/06/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
